Advancing Endometriosis Diagnosis

Proteomics International Laboratories (ASX: PIQ) has partnered with the University of Oxford, acquiring 600 clinical samples for its endometriosis study, aiming to enhance the clinical validation of its PromarkerEndo blood test. PromarkerEndo has shown promise by correctly identifying up to 90% of endometriosis cases in previous studies.

Endometriosis, affecting 1 in 9 women and girls, has long been challenging to diagnose, with current methods being invasive and taking an average of 7.5 years for a diagnosis. This collaboration signifies a step forward in developing a non-invasive, efficient diagnostic tool, potentially transforming the diagnostic landscape for endometriosis, a condition with significant economic and personal impact. The initiative aligns with efforts to improve diagnostic times and health outcomes for those suffering from this condition.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com